<DOC>
	<DOCNO>NCT00017407</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . ISIS 3521 may help kill cancer cell make tumor cell sensitive chemotherapy . It yet know carboplatin paclitaxel effective without ISIS 3521 . PURPOSE : Randomized phase III trial compare effectiveness carboplatin paclitaxel without ISIS 3521 treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Carboplatin Paclitaxel With Without ISIS 3521 Treating Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall survival patient stage IIIB IV non-small cell lung cancer treat carboplatin paclitaxel v without ISIS 3521 . II . Compare time tumor progression time treatment failure patient treat regimen . III . Compare overall ( complete plus partial ) response rate patient measurable disease treat regimen . IV . Compare percentage patient non-measurable , evaluable disease complete response treatment regimen . V. Compare duration response patient complete partial response treatment regimen . VI . Compare safety regimens patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord tumor stage ( IIIB v IV ) prior brain metastasis ( yes v ) . Patients randomize one two treatment arm . Arm I : Patients receive paclitaxel IV 3 hour carboplatin IV 1 hour day 0 . Arm II : Patients receive ISIS 3521 IV continuously day 0-14 paclitaxel IV 3 hour carboplatin IV 1 hour day 3 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Patients stable responsive disease receive 6 course treatment . Patients responsive disease may receive additional course treatment . Patients follow 1 , 2 , 4 , 6 month every 3 month thereafter . PROJECTED ACCRUAL : Approximately 600 patient ( 300 per treatment arm ) accrue study within 15 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IV OR Stage IIIB malignant pleural pericardial effusion At least 1 unidimensionally measurable lesion At least 10 mm spiral CT scan OR At least 20 mm standard technique OR Evaluable , nonmeasurable disease ( e.g. , ascites , bone metastasis , malignant pleural pericardial effusion ) No CNS metastases lesion locally treat surgery radiosurgery , provide evidence CNS progression least 4 week completion treatment No prior concurrent brain CNS metastases amenable local therapy ( e.g. , multiple brain lesion meningeal involvement ) Not candidate surgical treatment NSCLC PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10.0 g/dL No underlie disease associate active bleeding Hepatic : Bilirubin great 1.5 mg/dL AST le 3 time upper limit normal ( ULN ) ( 5 time ULN presence liver metastasis ) Renal : Creatinine great 1.5 mg/dL Other : No active infection require therapy No malignancy within past 5 year except carcinoma situ cervix nonmelanoma skin cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior approve experimental biologic therapy NSCLC Chemotherapy : No prior approve experimental chemotherapy NSCLC Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy recover No prior radiotherapy indicator lesion ( ) unless increase lesion size occur completion radiotherapy Concurrent localize palliative therapy allow preapproved sponsor Surgery : See Disease Characteristics Other : At least 30 day since prior participation investigational study No concurrent therapy NSCLC No concurrent experimental drug anticancer therapy active treatment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>